当前位置： SCI文献检索 > JOURNAL OF TRAVEL MEDICINE期刊下所有文献 > Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines.

Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines.

Abstract：

BACKGROUND:The purpose of this study was to evaluate the tolerance and immunogenicity of a hepatitis A vaccine using immunopotentiating reconstituted influenza virosomes (IRIV) as adjuvant when administered simultaneously with a yellow fever vaccine (YFV). METHOD:An open prospective trial with two parallel groups was conducted with 105 volunteers to study the effect of these vaccinations on the anti-hepatitis A virus (HAV) antibody response. Half of the volunteers (53) received one dose of IRIV-HAV vaccine (Epaxal) and one dose of live attenuated YFV (Stamaril) on the same day at two different sites. Fifty-six volunteers were given a single injection of IRIV-HAV as a control group. Anti-HAV titers were measured at days 14, 28, months 3, 12, 13, and 24 using a standardized test (Enzymun test Anti-HAV). Neutralizing yellow fever antibodies were measured at days 14 and 28 for the YFV recipients. Regarding vaccine tolerance, the volunteers were asked to record all their adverse reactions on a standard report sheet for the 6 days following the immunization. RESULTS:Seroconversion rates for HAV were 88% after 14 days and 100% after 4 weeks. There was no statistically significant difference between the two groups every time the titers were checked (IRIV-HAV vs HAV only: D14: 81 vs 101; D28: 275 vs 368; M3: 153 vs 169; M12: 117 vs 226; geometrical mean titers (GMT) in mIU/mL). However, lower titers were found among male volunteers, and were not attributable to YFV administration. The seroconversion rates for YFV were 90% after 14 days and 96% after 4 weeks. No serious general side-effects and only mild local reactions were reported. The administration of a booster of IRIV-HAV at 12 months resulted in a 24-fold increase in GMT. CONCLUSION:When needed, the simultaneous administration of the IRIV-HAV and YFV is immunogenic, safe and well-tolerated, as volunteers seroconverted to both antigens, with no cross-interference.

journal_name

J Travel Med

journal_title

Journal of travel medicine

authors

Bovier PA,Althaus B,Glueck R,Chippaux A,Loutan L

doi

10.1111/j.1708-8305.1999.tb00523.x

subject

Has Abstract

pub_date

1999-12-01 00:00:00

pages

228-33

issue

eissn

1195-1982

issn

1708-8305

journal_volume

pub_type

临床试验,杂志文章

在线工具

Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines.